Loading
A phase 1/2 trial of FLOT, CAPOX, Nivolumab in colorectal cancer and metastatic cancer, run by Parabilis Medicines, Inc., now recruiting.
FOG-001 in Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05919264 by Parabilis Medicines, Inc., with 619 participants planned, started 2023-05-23 and due to reach its primary completion in 2027-04-01. Interventions recorded: FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab. Conditions listed: Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor. No results are recorded here; the registry entry is the source.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Bevacizumab, Nivolumab.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Bevacizumab, Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Bevacizumab, Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Nivolumab, Metastatic cancer (cancer that has spread).
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Bevacizumab, Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.